Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Annals medicus

• Publication date

  2018-01-02

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/07853890.2017.1383629PMID 28929822
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Common Terminology Criteria for Adverse Events

  2020cited by this paper
• Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.

  2017influential reference
• Cardiovascular Toxic Effects of Targeted Cancer Therapies.

  2016cited by this paper
• VEGF-B gene therapy inhibits doxorubicin-induced cardiotoxicity by endothelial protection

  2016cited by this paper
• Ten years of anti-vascular endothelial growth factor therapy

  2016cited by this paper
• Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials.

  2015cited by this paper
• Trends in Prevalence, Awareness, Treatment and Control of Hypertension during 2001-2010 in an Urban Elderly Population of China

  2015cited by this paper
• Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.

  2015cited by this paper
• Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

  2015cited by this paper
• Etiology of angiogenesis inhibition-related hypertension.

  2015cited by this paper
• Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling: Potential Role in Metabolic Adaptation and Prevention of Progression.

  2015influential reference
• Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer.

  2015cited by this paper
• Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

  2015cited by this paper
• VEGF-C/VEGFR-3 pathway promotes myocyte hypertrophy and survival in the infarcted myocardium.

  2015cited by this paper
• Axitinib plasma pharmacokinetics and ethnic differences

  2015cited by this paper
• Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC

  2015cited by this paper
• Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery.

  2015cited by this paper
• Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.

  2014influential reference
• Genetic markers of bevacizumab-induced hypertension

  2014cited by this paper
• All anti-vascular endothelial growth factor drugs can induce 'pre-eclampsia-like syndrome': a RARe study.

  2014cited by this paper
• Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100

  2014cited by this paper
• QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors

  2014influential reference
• Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy

  2014cited by this paper
• Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients

  2013cited by this paper
• Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis of randomized clinical trials.

  2013cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

  2013cited by this paper
• Association between bevacizumab-related hypertension and vascular endothelial growth factor (VEGF) gene polymorphisms in Japanese patients with metastatic colorectal cancer

  2013cited by this paper
• Sorafenib in Advanced Hepatocellular Carcinoma: Hypertension as a Potential Surrogate Marker for Efficacy

  2013cited by this paper
• Prolyl 4 Hydroxylase: A Critical Target in the Pathophysiology of Diseases

  2013cited by this paper
• Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

  2013cited by this paper
• Epidermal growth factors in the kidney and relationship to hypertension.

  2013cited by this paper
• Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 3 AXIS Trial

  2013cited by this paper
• Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis

  2013cited by this paper
• The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer

  2013cited by this paper
• Cardiac Angiogenic Imbalance Leads to Peri-partum Cardiomyopathy

  2012cited by this paper
• Polymorphisms in Endothelial Nitric Oxide Synthase (eNOS) and Vascular Endothelial Growth Factor (VEGF) Predict Sunitinib‐Induced Hypertension

  2012cited by this paper
• Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen.

  2012cited by this paper
• Exploring racial differences in outcome and treatment for metastatic colorectal cancer

  2012cited by this paper
• Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database

  2012cited by this paper
• Ethnic Differences in Hypertension Incidence Among Middle-Aged and Older Adults: The Multi-Ethnic Study of Atherosclerosis

  2011cited by this paper
• Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Based Hybrid Patient and Physician Questionnaire for Head and Neck (HN) Radiotherapy Symptom Reporting

  2011cited by this paper
• Interaction Between Smoking and Polymorphism in the Promoter Region of the VEGFA Gene Is Associated with Ischemic Heart Disease and Myocardial Infarction in Rheumatoid Arthritis

  2011cited by this paper
• Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.

  2011influential reference
• Cardiovascular Imaging for Assessing Cardiovascular Risk in Asymptomatic Men Versus Women: The Multi-Ethnic Study of Atherosclerosis (MESA)

  2011cited by this paper
• Response: Re: Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cited by this paper
• Progression Is Accelerated From Prehypertension to Hypertension in Blacks

  2011cited by this paper
• Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

  2011cited by this paper
• Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease

  2011cited by this paper
• An observational study of bevacizumab-induced hypertension as a clinical biomarker of antitumor activity.

  2011cited by this paper
• Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

  2011cited by this paper
• Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies.

  2011influential reference
• Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients.

  2011cited by this paper
• Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

  2011cited by this paper
• Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials

  2010cited by this paper
• Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.

  2010cited by this paper
• Intramyocardial VEGF-B167 Gene Delivery Delays the Progression Towards Congestive Failure in Dogs With Pacing-Induced Dilated Cardiomyopathy

  2010cited by this paper
• Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

  2010cited by this paper
• ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations

  2010influential reference
• Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis

  2010cited by this paper
• The relationship of VEGF polymorphisms with serum VEGF levels and progression-free survival in patients with epithelial ovarian cancer.

  2010cited by this paper
• Overexpression of Vascular Endothelial Growth Factor 165 (VEGF165) Protects Cardiomyocytes Against Doxorubicin-Induced Apoptosis

  2010cited by this paper
• Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

  2010cited by this paper
• Why do kinase inhibitors cause cardiotoxicity and what can be done about it?

  2010influential reference
• Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis

  2009cited by this paper
• Polymorphisms in the WNK1 Gene Are Associated with Blood Pressure Variation and Urinary Potassium Excretion

  2009cited by this paper
• Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.

  2009cited by this paper
• Sunitinib (Sutent, SU11248), a Small-Molecule Receptor Tyrosine Kinase Inhibitor, Blocks Function of the ATP-Binding Cassette (ABC) Transporters P-Glycoprotein (ABCB1) and ABCG2

  2009cited by this paper
• VEGF single nucleotide polymorphisms (SNPs) and correlation to sunitinib-induced hypertension (HTN) in metastatic renal cell carcinoma (mRCC) patients (pts).

  2009cited by this paper
• Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.

  2009cited by this paper
• Electrocardiographic Characterization of the QTc Interval in Patients with Advanced Solid Tumors: Pharmacokinetic- Pharmacodynamic Evaluation of Sunitinib

  2009cited by this paper
• Evaluation of Hypertension as a Marker of Bevacizumab Efficacy

  2009cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.

  2008cited by this paper
• A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

  2008cited by this paper
• Vascular endothelial growth factor genetic variability and coronary artery disease in Brazilian population

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• VEGF inhibition and renal thrombotic microangiopathy.

  2008cited by this paper
• Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

  2008influential reference
• Polymorphisms of KDR gene are associated with coronary heart disease.

  2007cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Mechanisms of Disease: WNK-ing at the mechanism of salt-sensitive hypertension

  2007cited by this paper
• Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

  2007influential reference
• Polymorphisms of KDRGene Are Associated With Coronary Heart Disease

  2007cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper
• DNA sequence variation in the promoter region of the VEGF gene impacts VEGF gene expression and maximal oxygen consumption.

  2006cited by this paper
• Comparative Evaluation of HERG Currents and QT Intervals following Challenge with Suspected Torsadogenic and Nontorsadogenic Drugs

  2006cited by this paper
• Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs.

  2006cited by this paper
• An equilibrium partitioning model connecting gene expression and cis-motif content

  2006cited by this paper
• Predicting drug-hERG channel interactions that cause acquired long QT syndrome.

  2005cited by this paper
• Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters.

  2005cited by this paper
• VEGF polymorphisms and severity of atherosclerosis

  2005cited by this paper
• WNK1 Kinase Polymorphism and Blood Pressure Response to a Thiazide Diuretic

  2005cited by this paper
• High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter.

  2004cited by this paper
• Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

  2004cited by this paper
• IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines

  2003cited by this paper
• Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

  2003cited by this paper

• Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)

  2025cites this paper
• Health Equity in Cardio-oncology: Investigating Mechanistic Causes Behind Adverse Cardiovascular and Cancer Health

  2024cites this paper
• Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis

  2023cites this paper
• Cardiovascular Toxicity of Angiogenesis Inhibitors Among Patients With Cancer in Taiwan: A Nested Case‐Control Study

  2023cites this paper
• The cardioprotective potentials and the involved mechanisms of phenolic acids in drug-induced cardiotoxicity.

  2022cites this paper
• Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy

  2022cites this paper
• Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory‐differentiated thyroid cancer

  2022cites this paper
• Vascular endothelial growth factor modulates pulmonary vein arrhythmogenesis via vascular endothelial growth factor receptor 1/NOS pathway.

  2021cites this paper
• Tyrosine Kinase Inhibitors-Induced Arrhythmias: From Molecular Mechanisms, Pharmacokinetics to Therapeutic Strategies

  2021cites this paper